
See Dr. Gill’s publications here
1: le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399-1409.
2: Lane JM, Liang J, Vlasac I, Anderson SG, Bechtold DA, Bowden J, Emsley R, Gill S, Little MA, Luik AI, Loudon A, Scheer FA, Purcell SM, Kyle SD, Lawlor DA, Zhu X, Redline S, Ray DW, Rutter MK, Saxena R. Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits. Nat Genet. 2017 Feb;49(2):274-281.
3. Kwon JS, Albert AY, Gill S, Hutcheon JA. Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System. J Obstet Gynaecol Can. 2017 Jan;39(1):42-48.
4. Lentle B, Hammond I, Worsley D, Colquhoun A, Grochowski C, Leggett J, Gill S. A Qualitative Examination of the Ward Region of Interest as Imaged on Dual-Energy X-ray Absorptiometry Examinations: The “Wandering Ward Sign”. J Clin Densitom. 2016 Oct;19(4):515-521.
5. Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S. Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer Treat Rev. 2016 Nov;50:142-147.
6. Hasan H, Howard F, Morgan SG, Metzger DL, Lo AC, Goddard K, Gill S, Johnson M. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada. Healthc Policy. 2014 Feb;9(3):80-96.